Clinical Investigation of Treatment Failure in Type 2 Diabetic Patients Treated with Metformin and Glibenclamide at a Hospital in Northwestern Nigeria
Purpose: To examine body mass index (BMI), occupation, sex, age, and duration of therapy as contributory factors in treatment failure in type 2 diabetic patients taking metformin and glibenclamide in a tertiary hospital in Northwestern Nigeria.
Method: A retrospective case control study was employed where variables (age, sex, body mass index, tribe, duration of therapy, glycaemic profile and occupation) for a total of 520 type 2 diabetic patients that took metformin and glibenclamide for a minimum of 1 year were examined. Patients were classified into two groups based on progression to triple oral therapy or a switch from metformin and glibenclamide therapy.
Results: Of the 520 patients analysed, 276 failed treatment. Over 90 % of the patients were > 40 years while 61 % had been on treatment for > 4 years. The subjects’ mean age was 53.22 ± 9.03 years. The mean population body mass index (BMI) was 27 kg/m2. Housewives comprised more than half of the population (55.5 %). The mean fasting blood glucose and 2 h post prandial blood glucose levels of group 1 were 5.99 ± 0.67 mmol/L and 8.76 ± 2.19 mmol/L respectively while the corresponding values for group 2 were 12.55 ± 4.12 mmol/L and 18.42 ± 5.3 mmol/L, respectively.
Conclusion: Progressive deterioration in pancreatic ß-cell function, BMI > 28 kg/m2, advancing age, and young age at diagnosis were identified as contributory factors to the development of secondary failure in type 2 diabetics receiving metformin and glibenclamide.
Keywords: Diabetes, Glibenclamide, Metformin, Pancreatic ß-cell function, Treatment failure
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.